spacer
home > ebr > summer 2007 > small but perfectly formulated
PUBLICATIONS
European Biopharmaceutical Review

Small but Perfectly Formulated

The total US market for nanomedicines will command strong growth over the long term, rising to over $39 billion in 2011, says William Martineau at Freedonia Group, sustaining a strong upward pace to $82 billion in 2016

Trends in the US pharmaceutical industry will favour the increasing development of nanotechnology drug formulations and delivery systems. The high costs and extensive regulatory requirements involved in commercialising new therapies will prompt proprietary pharmaceutical manufacturers to diversify research and development strategies into product line extensions. Reformulations and drug delivery systems provide a costeffective means to improve the safety, efficacy and convenience of existing medication. In most cases, improved versions of existing medication are subject to less stringent clinical testing standards than new therapies. As a result, the commercialisation timetable is shorter and less costly. More importantly, a multiple source drug adapted to a unique delivery system can sometimes gain new or extended patent protection, providing its developer with significant competitive advantages.

Nanomedicines are pharmaceuticals and biologicals composed of nanoscale active ingredients or adapted to nanoparticle delivery systems. Monoclonal antibodies comprise the principal nanoscale active ingredients now employed in therapeutic applications and 20 such therapies have been approved for use by the FDA. In addition, more than 150 new monoclonal antibody drugs are being tested in US clinical trials. In commercial use, nanoparticle drug delivery agents consist of crystals, liposomes and polymers. Dendrimers, fullerenes, micelles, nanoshells and nanowires are among the nanoparticle drug delivery agents in various stages of development.

MONOCLONAL ANTIBODIES

Discovered in the mid-1970s, monoclonal antibodies meet the definition of nanomaterials, being on average just 20 nanometres in size. They are protein molecules produced through hybridoma technology. A hybridoma is a biological manufacturing factory created by fusing together two cells of different origins. One cell incorporates a gene that stimulates the production of an antibody specific to a single target, such as an antigen or antigen receptor site. The other cell is derived from a mouse and contains an indestructible, continuously dividing tumour. The fused hybridoma produces an unlimited supply of monoclonal antibodies that will respond or react to only one specific stimuli.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
William Martineau is an authority on the health care industry. He has performed in-depth research across biotechnology, pharmaceuticals, medical packaging and related areas, producing titles such as: Pharmaceutical Chemicals, US Pharmaceutical Packaging, World Pharmaceutical Packaging, World Pharmaceuticals I & II, Medical Testing Chemicals, Drug Delivery Systems, and Biotechnology. Prior to joining Freedonia, he was Manager of Market Development at American Sterilizer Company, where he gained experience in health care research and strategic planning. At Invenex Laboratories, he served as Product Manager, responsible for the administration of a line of injectable pharmaceuticals. He also served as Senior Health Care Analyst at Predicasts Inc and Manager of Market Research at Life Technologies Inc (a division of The Dexter Corporation). William holds a BA in Management and an MBA in Marketing and Finance from Kent State University.
spacer
William Martineau
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement